Isolere Bio Returns to ASGCT with Big News for Small-Scale AAV Purification
The Isolere Bio team is excited to announce our attendance at ASGCT's 29th Annual Meeting next month in Boston, Massachusetts! This year, the team will be focused on sharing some exciting insights on how IsoTag™ AAV reagent can be used as a quick, simple, low touch-point purification solution to help scientists screen candidates and test optimization parameters for multiple AAV samples in parallel. If you’re planning to be in Boston for ASGCT 2026, here are some places where you can find us:
Tuesday, May 12 - Thursday, May 14
We’d love to see you in-person at Booth #1630!
Our Business Development Manager, Ashley Wilson, and Sr. Field Application Specialist, Tori Robinson, will be handing out giveaways and explaining the fully reversible, phase separation technology that allows IsoTag™ reagents to separate target biologics from cellular contaminants without the use of chromatography resins or ultracentrifugation. Be sure to stop by or schedule a specific time to meet with the team!
Jennifer Haley, Associate Director, Applications Development
Simple and Rapid Small-Scale AAV Purification Ssing a Novel IsoTag™ AAV Reagent with Low-Speed Centrifugation
Session Title: Welcome and Poster Reception
Date: Tuesday, May 12, 2026
Time: 5:00 PM - 6:30 PM ET
Presentation ID: 1162
Advances in AAV engineering to enhance tissue tropism, improve DNA packaging efficiency and reduce immunogenicity have accelerated in recent years, driving demand for early-development platforms capable of producing and screening large numbers of candidates in parallel. While advances have been made in scaled-down upstream production and high-throughput analytical techniques, accessible small-scale purification remains a bottleneck. The IsoTag™ AAV reagent enables small-scale purification of AAV harvest samples in parallel in as little as 2 hours without the use of resins or ultracentrifugation. The IsoTag™ technology is a novel protein reagent that combines an affinity ligand with a stimulus responsive, phase-separating biopolymer. This technology leverages fully reversable Affinity Liquid Phase Separation (ALPS) to achieve AAV separation on the basis of affinity and size in a single process. Upon binding AAV capsids, the liquid-liquid phase separation is triggered, sequestering AAV into droplets that can be pelleted using low speed centrifugation, enabling the removal of contaminants and media components. The captured AAV is then separated from the IsoTag AAV reagent using a chilled elution buffer. This process is performed using standard laboratory equipment with minimal variability in results between experienced and novice users. The IsoTag™ AAV reagent has shown affinity for a variety of serotypes including 1, 2, 6, 8, 9, PHP.B and a range of engineered capsids. AAV9 capture efficiency >90% has been shown across a range of volumes from 0.1mL to 40mL in the same 2-hour time frame. Elution recoveries of up to 80% have been shown with AAV9 in volumes of 1 mL to 40 mL using low, neutral or high pH elution buffers. This simple and rapid AAV purification method has the potential to remove bottlenecks in early development workflows and accelerate screening and advancement of next generation of AAV therapeutic candidates.
Authors: Jennifer Haley, Tori Robinson, Alyssa Wheeler, Michael Dzuricky, PhD